HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

nangibotide

Also Known As:

LR-12; Motrem; lissamine-rhodamine dodecanoic acid

Networked: 8 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Lauric Acids: 8
    - nangibotide: 8
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - nangibotide: 8
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Xanthenes: 65
      - Rhodamines: 466
        nangibotide: 8

Experts

1.	Derive, Marc: 3 articles (01/2021 - 10/2018)
2.	Gibot, Sebastien: 3 articles (01/2021 - 12/2016)
3.	Salcedo-Magguilli, Margarita: 3 articles (01/2021 - 10/2018)
4.	Witte, Stephan: 3 articles (01/2021 - 10/2018)
5.	Cuvier, Valerie: 2 articles (01/2021 - 10/2018)
6.	Laterre, Pierre-François: 2 articles (01/2021 - 07/2020)
7.	Olivier, Aurelie: 2 articles (01/2021 - 10/2018)
8.	Garaud, Jean-Jacques: 2 articles (07/2020 - 10/2018)
9.	Chen, Hongjie: 1 article (06/2022)
10.	Lu, Haiming: 1 article (06/2022)

Related Diseases

1.	Septic Shock (Toxic Shock Syndrome) 07/01/2020 - "Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. " 01/01/2021 - "Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock is a phase IIb randomised controlled trial that will take place in up to 50 centres in seven countries and recruit 450 patients with septic shock to receive either placebo or one of two doses of nangibotide, a novel regulator of the TREM-1 pathway. " 01/01/2021 - "Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial." 07/01/2020 - "This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodynamic parameters in septic shock patients. " 07/01/2020 - "Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial."
2.	COVID-19 06/01/2023 - "Whilst the study was stopped early due to low recruitment rate, the ESSENTIAL study demonstrated that TREM-1 modulation with nangibotide is safe in COVID-19, and results in a consistent pattern of improved clinical status and mortality compared to placebo. " 06/01/2023 - "Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial." 10/01/2023 - "Nangibotide for precision immunomodulation in septic shock and COVID-19."
3.	Atherosclerosis 12/27/2016 - "Genetic invalidation of Trem-1 in ApoE-/-/Trem-1-/- mice or pharmacological blockade of Trem-1 in ApoE-/- mice using LR-12 peptide also significantly reduced the development of atherosclerosis throughout the vascular tree, and lessened plaque inflammation. "
4.	Pneumonia (Pneumonitis) 06/01/2023 - "The relationship between sTREM-1 and both risk of death and treatment response merits further evaluation of nangibotide using precision medicine approaches in life threatening viral pneumonitis. "
5.	Osteoarthritis 06/01/2022 - "Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone."

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Peptides (Polypeptides)
3.	Apolipoproteins E (ApoE)
4.	Triggering Receptor Expressed on Myeloid Cells-1

Related Therapies and Procedures

1.	Precision Medicine
2.	Immunomodulation
3.	Therapeutics